Oral squamous cell carcinoma affects about 30,000 Americans each year, and although the overall prognosis has improved in recent years for localized carcinomas, metastases can decrease survival rates by half. For tongue and palate lesions, surgery is usually the initial treatment, but distant metastases can develop at sites where conventional therapies are ineffective (lung, bone, heart). Therefore, our goal has been to develop a fast‐growing orthotopic stromal‐epithelial SCC model with a metastasis profile, in which to test new adenoviral‐based gene therapies. We specifically plan to use systemic delivery of an adenovirus (Ad) that targets expression of therapeutic gene p12/CDK2AP1 to SCC cells using the SCCA2 promoter and a transcriptional amplification system. We developed new orthotopic stromal‐epithelial SCC models for floor of mouth and tongue carcinoma with rapid latency and partial tumor spread to regional lymphnodes. We constructed and are characterizing an Ad‐TSTA‐p12FL bidirectional vector for gene therapy applications. We plan to test in vivo the specificity of the vector, the effectiveness in tumor growth inhibition at both floor of mouth, orthotopic, or distant sites, and following intratumoral or systemic administration. We propose this vector may hold promise as a specific, novel, and robust SCC therapy to treat tumors that have metastasized to distant and thus difficult to treat sites.
Read full abstract